Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Near-Infrared Light Therapy Combined With Lecanemab for Mild Alzheimer's Disease — Stella

Home/Alzheimer Disease/

View on ClinicalTrials.gov

Recruiting

Back to Alzheimer Disease trials

Early Phase 1 — Very small initial tests in humans, typically just a few people, to make sure the treatment is safe enough to study further.

Trial locations(1 site)

China

Xuanwu Hospital, Capital Medical University, Beijing

Key details

Phase

Very early testing

Sponsor

Xuanwu Hospital, Beijing

Enrollment target

~20 participants

Started

May 2025

Primary completion

October 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

50 Years – 90 Years

Last updated September 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.